Recruiting studies: Msi H Or Dmmr Advanced Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Phase 1 · 22 location(s) · Amgen · NCT07403721 KN035 for dMMR/MSI-H Advanced Solid Tumors
Phase 2 · 1 location(s) · 3D Medicines (Sichuan) Co., Ltd. · NCT03667170 Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2 · 30 location(s) · BeiGene · NCT03736889 A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Phase 1 · 1 location(s) · Jemincare · NCT07208136 A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692 Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Phase 2 · 1 location(s) · Fudan University · NCT07003022 EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combinatio
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT07262619 Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 15 location(s) · MOMA Therapeutics · NCT06974110

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.